Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: The CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (CanACTFAST) study

Canadian Journal of Cardiology

Volumn 26, Issue 2, 2010, Pages 80-86

  Ur, Ehud ^a   Langer, Anatoly ^b   Rabkin, Simon W ^a   Calciu, Cristina Dana ^c   Leiter, Lawrence A ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PFIZER INC   (United States)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Cholesterol; Coronary artery disease; Diabetes mellitus; Dyslipidemias; Hypercholesterolemia; Statin

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; MYOPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RHABDOMYOLYSIS; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CANADA; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FOLLOW UP; HYPERCHOLESTEROLEMIA; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADULT; AGED; CANADA; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRROLES; RISK FACTORS; TREATMENT OUTCOME;

EID: 77949325404     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(10)70003-9     Document Type: Article

References (25)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389
2. Sacks FM, Pfeffer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009 (Pubitemid 26338729)
3. Baignet C, Keech A, Kearney PM, et al; for the Cholesterol Treatment Trialists (CTT) Collaboration. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005;366:1267-1278
4. McPherson R, Frohlich J, Fodor G; for the Canadian Cardiovascular Society. Canadian Cardiovascular Society Position Statement. Recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913-927 (Pubitemid 44596492)
5. Fodor JG, McPherson R, Dafoe WA, Grenville A. Investigation and treatment of hypercholesterolemia and other dyslipidemias in Canadian primary care practice. CVD Prevention 1998;1:225-230
6. Hackam DG, Tan MK, Honos GN, Letier LA, Langer A, Goodman SG; for the Vascular Protection Registry Investigators. How does the prognosis of diabetes compare with that of established vascular disease? Insights from the Canadian Vascular Protection (VP) Registry. Am Heart J 2004;148:1028-1033
7. Yan AT, Yan RT, Tan M, et al; for the Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries Investigators. Contemporary management of dyslipidemia in high-risk patients: Targets still not met. Am J Med 2006;119:676-683
8. Austin PC, Mamdani MM, Juurlink DN, Alter DA, Tu JV. Missed opportunities in the secondary prevention of myocardial infarction: An assessment of the effects of statin underprescribing on mortality. Am Heart J 2006;151:969-975
9. Fodor JG, Frohlich JJ, Genest JJ Jr, McPherson PR. Recommendations for the management and treatment of dyslipidemia. Report on the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ 2000;162:1441-1447
10. Bourgault C, Davignon J, Fodor G, et al. Statin therapy in Canadian patients with hypercholesterolemia: The Canadian Lipid Study - Observational (CALIPSO). Can J Cardiol 2005;21:1187-1193 (Pubitemid 43013529)
11. McPherson R, Angus C, Murray P, Genest J. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease. The Women's Atorvastatin Trial on Cholesterol (WATCH). Am Heart J 2001;152:489-496
12. Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: Results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007;115:700-707 (Pubitemid 46294760)
13. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004;291:1071-1080 (Pubitemid 38541684)
14. Martineau P, Gaw A, de Teresa E, et al. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: The Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. Atherosclerosis 2007;191:135-164 (Pubitemid 46227412)
15. Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary of the 2003 update. CMAJ 2003;169:921-924
16. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 2001;285:2486-2497
17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
18. Aguilar-Salinas C, Gomez-Perez F, Posadas-Romero C, et al. Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study. Atherosclerosis 2000;152:489-496
19. Andrew T, Ballantyne See, Hsia J, Kramer J. Achieving and maintaining National Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001;111:185-191 (Pubitemid 32786945)
20. Foley KA, Simpson Jr RJ, Crouse III JR, Weiss TW, Markson LE, Alexander CM. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003;92:79-81.
21. Brown A, Bakker-Arkema R, Yellen L, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 1998;32:665-672 (Pubitemid 28435251)
22. Jones PH, McKenney JM, Kardis DG, Downey J. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am Heart J 2005;9:98-101. (Pubitemid 40126481)
23. Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,326 patients. Am J Cardiol 2006;97:61-67 (Pubitemid 41828124)
24. LaRosa JC, Grundy SM, Waters DD, et al; for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New Engl J Med 2005;352:1425-1435
25. Jacevicius CA, Mamdani M, Tu JV. Adherence to statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2000;288:462-467